What is the recommended dose of progesterone (micronized progesterone) for a pregnancy with subchorionic hemorrhage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Progesterone Dosing for Pregnancy with Subchorionic Hemorrhage

For pregnancies with subchorionic hemorrhage, vaginal micronized progesterone at a dose of 400 mg twice daily is recommended based on the strongest available evidence.

Evidence-Based Recommendations

Vaginal Progesterone

  • Vaginal micronized progesterone 400 mg twice daily is the most studied and effective dose for threatened miscarriage with subchorionic hemorrhage 1, 2
  • This dosage has been shown to increase live birth rates in women with threatened pregnancy loss, particularly in those with a history of previous miscarriages 1
  • The PRISM trial demonstrated that vaginal micronized progesterone at this dose was associated with a 5% increase in live birth rates for women with previous miscarriage(s) and current pregnancy bleeding 1
  • For women with three or more previous miscarriages and current bleeding, the benefit was even greater with a 15% increase in live birth rates 1

Alternative Progesterone Options

  • Oral dydrogesterone 40 mg/day has shown efficacy in some studies with a reported abortion rate of only 7% in women with subchorionic hematoma 3
  • Some evidence suggests oral progesterone 400 mg daily may be beneficial in preventing preterm birth, though with less robust evidence than vaginal administration 4

Duration of Treatment

  • Treatment should be continued until complete resolution of the subchorionic hematoma 5
  • In studies examining preterm birth prevention, progesterone therapy typically continued until 34-37 weeks of gestation 4

Monitoring and Expected Outcomes

  • Regular ultrasound monitoring should be performed to assess hematoma resorption 5, 6
  • Patients treated with progesterone typically show faster resorption of subchorionic hematoma compared to untreated controls 5
  • Monitor for resolution of clinical symptoms including vaginal bleeding and pelvic pain 6

Potential Adjunctive Therapies

  • Some preliminary evidence suggests that alpha lipoic acid (ALA) may enhance the effectiveness of progesterone therapy in resolving subchorionic hematomas 5, 6
  • In a small trial, the combination of progesterone 400 mg daily (200 mg twice daily) vaginally plus oral ALA 600 mg daily (300 mg twice daily) showed faster hematoma resorption than progesterone alone 5

Clinical Considerations and Caveats

  • While most guidelines focus on progesterone for preterm birth prevention rather than specifically for subchorionic hemorrhage, the evidence for threatened miscarriage (which includes subchorionic hemorrhage) supports the 400 mg twice daily vaginal dose 1, 2
  • The benefit of progesterone appears greater in women with a history of previous miscarriages 1
  • No short-term safety concerns have been identified with vaginal micronized progesterone at this dose 1
  • There is insufficient evidence to recommend 17-alpha-hydroxyprogesterone caproate (17P) specifically for subchorionic hemorrhage, as most studies with this formulation focused on preventing recurrent preterm birth 4

References

Research

[Treatment of threatened pregnancy loss].

Ugeskrift for laeger, 2025

Research

Subchorionic hemorrhage treatment with dydrogesterone.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2007

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Alpha Lipoic Acid (ALA) effects on subchorionic hematoma: preliminary clinical results.

European review for medical and pharmacological sciences, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.